Commercialize Western Tech in Chinese Market

Bridge Point Solutions

Bridge Point Capital is a growth-focused cross-border Private Equity and Strategic Advisory firm with a unique expertise in monetizing and marketing disruptive Healthcare technology. We are able to help western companies access the China market as well as help Chinese firms develop business opportunities in the U.S.

Cross-border Market Entry

U.S/China market penetration

  • Joint Ventures

  • Licensing deals

  • Subsidiaries

Strategic Alliances & Planning

Mergers and Acquisitions

Value Chain improvement

Innovative Financing Strategy

Customized financing methods

Special Purpose
Acquisition Company

Traditional & non-
traditional exit strategies

Product development

Implement best practices

Monetization of technology

Innovative market strategies

Working capital optimization

Health-Tech Commercialization

Work directly with private insurers

Target self-insured employer
groups and Taft-Hartley funds

Non-traditional, alternative reimbursement strategies

Third Party Reimbursement

Assist with licensing pharma deals

Expedite process to aid licensing approval

Sourcing profitable In-licensing opportunities

Licensing

Licensing Timeline

Bridge Point Advisory utilizes our deep China expertise, proprietary network of U.S healthcare and financial institutions to help Chinese pharmaceutical distributors to commercialize Western products. We aim to create long-term value for our clients from assisting with partner sourcing all the way to deal structuring and deal closing.

2 weeks

2 - 4 weeks

1 month

Research on Positioning & China Market

Identify Prospective Partners

Partnership Materials & Outreach

Partnership Due Diligence

1 month

Deal Structuring & Economics

3 - 4 weeks

Transaction Negotiation

1 - 2 months

Transaction Closing

1 month

CONTACT US

152 W57th Street, Carnegie Hall Tower, 49th Floor, New York

NY, 10019

info@bridgepoint.capital

WeChat